Brighthouse Financial (BHF) Q2 2024 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2024 earnings summary
2 Feb, 2026Executive summary
Net income available to shareholders was $9 million ($0.12 per share) in Q2 2024, compared to a net loss of $200 million in Q2 2023, with adjusted earnings rising to $346 million ($5.57 per share) from $271 million year-over-year.
Record life sales in the first half of 2024, up 19% year-over-year; annuity sales were flat compared to 2023, with record Shield Level Annuity sales exceeding $2 billion in Q2.
Holding company liquid assets totaled $1.2 billion at quarter-end, with statutory combined total adjusted capital of $5.4 billion, down from $6 billion at March 31.
Repurchased $151 million of common stock year-to-date through August 2, 2024, including $64 million in Q2.
Preliminary statutory results were disappointing due to a decline in the RBC ratio to 380%-400%, below the 400%-450% target range in normal markets.
Financial highlights
Q2 2024 total revenues were $1.43 billion, up from $263 million in Q2 2023, reflecting improved investment income and lower derivative losses.
Net investment income was $1.31 billion in Q2 2024, with an adjusted net investment income yield of 4.39%.
EPS for Q2 2024 was $0.12, compared to $(3.01) in Q2 2023.
Book value excluding AOCI was $7.9 billion ($128.36 per share) at quarter-end.
Year-to-date through August 2, $151 million of common stock was repurchased.
Outlook and guidance
Expect to restore the RBC ratio to the 400%-450% target range by year-end 2024, with multiple capital initiatives, including reinsurance, underway to improve capital efficiency within 6–12 months.
Anticipate full-year 2024 corporate expenses to be lower than 2023, despite expected increases in the second half due to seasonality.
Management remains confident in strong capitalization and liquidity position.
Expect uneven inflows from LifePath Paycheck, with limited activity in Q3 and more in Q4.
Latest events from Brighthouse Financial
- Q4 net income declined, but record annuity and life sales and a pending $4.1B acquisition marked 2025.BHF
Q4 202523 Feb 2026 - Merger and related proposals were approved by stockholders as recommended by the board.BHF
EGM 202612 Feb 2026 - Shareholders to vote on merger amid litigation and board's unanimous support.BHF
Proxy Filing4 Feb 2026 - Adjusted earnings surged on actuarial gains, with life sales up 19% and capital actions ongoing.BHF
Q3 202415 Jan 2026 - Shareholders to vote on $70/share cash merger with Aquarian Holdings; board recommends approval.BHF
Proxy Filing7 Jan 2026 - Q4 2024 net income was $646M, with record annuity and life sales and strong capital metrics.BHF
Q4 202426 Dec 2025 - Shareholders to vote on $70.00 per share cash merger, with board unanimous in recommending approval.BHF
Proxy Filing23 Dec 2025 - Preliminary proxy outlines annual meeting proposals and board governance for shareholder vote.BHF
Proxy Filing1 Dec 2025 - Shareholders to vote on directors, auditor, executive pay, and updated incentive plan amid strong strategic progress.BHF
Proxy Filing1 Dec 2025